Phase II Study of [18F]RGD-K5 in Head and Neck Cancer Patients
This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration
is expected to be completed in a period of 3 year. Up to 100 patients would be included.
Group A would be those to undergo surgical excision or biopsy (n=20); Group B would be those
with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy
(n=40); and Group C would be those with M1 disease to receive biotherapy or chemotherapy
(n=40). Group A patients could be included into Group B or C if qualified. Each participant
must fulfill all the inclusion and exclusion criteria.
Time Perspective: Prospective
Taiwan: Department of Health